The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Clinical cancer research, 2016-11, Vol.22 (22), p.5527-5538 [Peer Reviewed Journal]2016 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-16-0569 ;PMID: 27780853
Full text available